Ruth Goodall, Senior Statistician

Ruth has over 20 years of experience in infectious disease research having joined the Unit in 1997 as a postgraduate student, completing her PhD in methods for the analysis of interval-censored data motivated by her work alongside in early trials of HIV treatment. Initially focusing on HIV infection, Ruth has worked on Phase I-III clinical trials of treatment strategies, preventative vaccines and immunotherapy (FORTE, INITIO, OPTIMA, EV01, HCQ-01, KONCERT), and observational studies focusing on the evolution of drug resistance in adults (DART) and treatment responses in children and adolescents (EPPICC, CHIPS+, CIPHER).

More recently Ruth joined the TB programme as a trial statistician for STREAM. Stage 1 of the STREAM trial showed a 9-month treatment regimen for rifampicin-resistant TB was as effective as the 20-month regimen recommended by WHO at the time. Stage 2 of STREAM was the registrational trial for bedaquilline and demonstrated that 2 bedaquilline-containing regimens were superior to the 9-month regimen evaluated in Stage 1.

Ruth is currently the Institute lead for the WHO TB-IPD platform, a data curation project for TB treatment trials and observational datasets.

Selected publications

The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration (2020). Outcomes of second‐line antiretroviral therapy among children living with HIV: a global cohort analysis. JIAS, 23(4): e25477. doi: 10.1002/jia2.25477

European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group. (2019). Height and timing of growth spurt during puberty in young people living with vertically acquired HIV in Europe and Thailand. AIDS, 33(12):1897-1910. doi: 10.1097/QAD.0000000000002294.

Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration. (2019). Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration. Lancet HIV, 6(2):e105-e15. doi: 10.1016/S2352-3018(18)30319-9.

The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Cohort Collaboration Cohort Team. (2018). The epidemiology of adolescents living with perinatally-acquired HIV: a cross-region global cohort analysis. PLOS Medicine, 15(3) doi: 10.1371/journal.pmed.1002514

European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord. (2018). Long term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV in Europe and Thailand: cohort study. PLOS Medicine, 15(1) doi: 10.1371/journal.pmed.1002491

Dolling, D. I., Goodall, R. L., Chirara, M., Hakim, J., Nkurunziza, P., Munderi, P., . . . DART Virology Group. (2017). The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data. BMC Infectious Diseases, 17(1), 160. doi:10.1186/s12879-017-2266-3

Paediatric European Network for Treatment of AIDS. (2015). Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children. AIDS, 29(18), 2447-2457. doi:10.1097/QAD.0000000000000862

Paton, N. I., Goodall, R. L., Dunn, D. T., Franzen, S., Collaco-Moraes, Y., Gazzard, B. G., . . . Hydroxychloroquine Trial Team. (2012). Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA: Journal of the American Medical Association, 308, 353-361. doi: 10.1001/jama.2012.6936.

Research Interests

  • MDR-TB
  • HIV in children and young people
  • Design and analysis of clinical trials and observational studies

Research Areas

UCL Profiles